MX341660B - Agonista del receptor de ghrelina para el tratamiento de caquexia. - Google Patents
Agonista del receptor de ghrelina para el tratamiento de caquexia.Info
- Publication number
- MX341660B MX341660B MX2012009774A MX2012009774A MX341660B MX 341660 B MX341660 B MX 341660B MX 2012009774 A MX2012009774 A MX 2012009774A MX 2012009774 A MX2012009774 A MX 2012009774A MX 341660 B MX341660 B MX 341660B
- Authority
- MX
- Mexico
- Prior art keywords
- compound
- dyscrasia
- treatment
- pharmaceutical composition
- receptor agonist
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
Abstract
La presente invención se relaciona con el uso de un compuesto de la presente invención o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal, para la manufactura de un medicamento para el tratamiento de caquexia. La invención también se refiere con un método para el tratamiento de caquexia, el cual comprende la administración del compuesto de la presente invención, o una composición farmacéutica que comprende el mismo a un ser humano o a un animal. La invención además se refiere al uso de dicho compuesto, o una sal farmacéuticamente aceptable de éste, o una composición farmacéutica que comprende el compuesto o la sal, en combinación con uno o más segundos agentes activos. Más aún, la invención se refiere a una composición farmacéutica y a un kit que comprende el compuesto de la presente invención o una sal farmacéuticamente aceptable de éste, para el tratamiento de la caquexia.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2010043484 | 2010-02-26 | ||
| PCT/JP2011/054556 WO2011105611A1 (ja) | 2010-02-26 | 2011-02-28 | 悪液質を治療するためのグレリン受容体作動物質 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2012009774A MX2012009774A (es) | 2012-10-05 |
| MX341660B true MX341660B (es) | 2016-08-29 |
Family
ID=44507004
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012009774A MX341660B (es) | 2010-02-26 | 2011-02-28 | Agonista del receptor de ghrelina para el tratamiento de caquexia. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10975070B2 (es) |
| EP (1) | EP2540721B1 (es) |
| JP (1) | JPWO2011105611A1 (es) |
| KR (1) | KR20120131183A (es) |
| CN (1) | CN102762564B (es) |
| BR (1) | BR112012020377B1 (es) |
| CA (1) | CA2789750C (es) |
| ES (1) | ES2615731T3 (es) |
| FR (1) | FR23C1048I1 (es) |
| HK (1) | HK1174615A1 (es) |
| MX (1) | MX341660B (es) |
| RU (1) | RU2012141061A (es) |
| WO (1) | WO2011105611A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210009438A (ko) * | 2012-09-27 | 2021-01-26 | 아라타나 세라퓨틱스, 인크. | 식욕부진을 조절 화합물 조성물 및 이의 이용 방법 |
| RU2670978C9 (ru) * | 2013-05-28 | 2018-11-22 | Раквалиа Фарма Инк. | Полиморфные формы |
| JP2017532350A (ja) * | 2014-10-31 | 2017-11-02 | ラクオリア創薬株式会社 | グレリン受容体アゴニストとしてのテトラヒドロピラゾロピリジン誘導体 |
| KR20170097212A (ko) * | 2015-01-28 | 2017-08-25 | 아라타나 세라퓨틱스, 인크. | 체중-증량 화합물의 장기 사용을 위한 조성물 및 방법 |
| EP4218757A1 (en) * | 2020-09-22 | 2023-08-02 | Kyungpook National University Industry-Academic Cooperation Foundation | Use of triazole compound as ghrelin receptor agonist |
| CN115778960A (zh) * | 2022-08-19 | 2023-03-14 | 广州六顺生物科技有限公司 | 一种杂芳环衍生物在制备治疗或预防恶病质药物中的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4997984A (en) | 1989-12-19 | 1991-03-05 | Shawa Denko K.K. | Process for preparation of N-(α-alkoxyethyl)-carboxylic acid amide |
| TW432073B (en) | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
| ATE446758T1 (de) | 2000-05-31 | 2009-11-15 | Pfizer Prod Inc | Verwendung von wachstumshormonsekretagoga zur förderung der beweglichkeit des verdauungstrakts |
| IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
| AU2005277389A1 (en) | 2004-08-18 | 2006-03-02 | Elixir Pharmaceuticals, Inc. | Growth-hormone secretagogues |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| MX2009008561A (es) * | 2007-02-13 | 2010-01-15 | Helsinn Therapeutics Us Inc | Metodo para tratar trastornos proliferativos celulares utilizando secretagogos. |
| WO2008153027A1 (ja) | 2007-06-11 | 2008-12-18 | Takeda Pharmaceutical Company Limited | ピロロキノリン誘導体およびその用途 |
| WO2009063993A1 (ja) | 2007-11-15 | 2009-05-22 | Takeda Pharmaceutical Company Limited | 縮合ピリジン誘導体およびその用途 |
| WO2009139340A1 (ja) * | 2008-05-12 | 2009-11-19 | 武田薬品工業株式会社 | ピラゾール化合物 |
| KR20210009438A (ko) | 2012-09-27 | 2021-01-26 | 아라타나 세라퓨틱스, 인크. | 식욕부진을 조절 화합물 조성물 및 이의 이용 방법 |
-
2011
- 2011-02-28 EP EP11747565.7A patent/EP2540721B1/en active Active
- 2011-02-28 CN CN201180009948.8A patent/CN102762564B/zh active Active
- 2011-02-28 MX MX2012009774A patent/MX341660B/es active IP Right Grant
- 2011-02-28 RU RU2012141061/04A patent/RU2012141061A/ru not_active Application Discontinuation
- 2011-02-28 BR BR112012020377-0A patent/BR112012020377B1/pt active IP Right Grant
- 2011-02-28 KR KR1020127024117A patent/KR20120131183A/ko not_active Application Discontinuation
- 2011-02-28 ES ES11747565.7T patent/ES2615731T3/es active Active
- 2011-02-28 CA CA2789750A patent/CA2789750C/en active Active
- 2011-02-28 JP JP2012501911A patent/JPWO2011105611A1/ja active Pending
- 2011-02-28 US US13/580,479 patent/US10975070B2/en active Active
- 2011-02-28 WO PCT/JP2011/054556 patent/WO2011105611A1/ja active Application Filing
-
2013
- 2013-01-31 HK HK13101402.5A patent/HK1174615A1/xx unknown
-
2021
- 2021-03-02 US US17/189,552 patent/US20210179613A1/en not_active Abandoned
-
2023
- 2023-12-18 FR FR23C1048C patent/FR23C1048I1/fr active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10975070B2 (en) | 2021-04-13 |
| EP2540721B1 (en) | 2016-12-14 |
| HK1174615A1 (en) | 2013-06-14 |
| US20210179613A1 (en) | 2021-06-17 |
| BR112012020377A8 (pt) | 2018-01-02 |
| BR112012020377B1 (pt) | 2019-10-08 |
| FR23C1048I1 (fr) | 2024-01-19 |
| RU2012141061A (ru) | 2014-04-10 |
| CN102762564A (zh) | 2012-10-31 |
| JPWO2011105611A1 (ja) | 2013-06-20 |
| WO2011105611A1 (ja) | 2011-09-01 |
| CA2789750A1 (en) | 2011-09-01 |
| EP2540721A1 (en) | 2013-01-02 |
| ES2615731T3 (es) | 2017-06-08 |
| CN102762564B (zh) | 2015-09-30 |
| US20120322821A1 (en) | 2012-12-20 |
| EP2540721A4 (en) | 2013-08-07 |
| KR20120131183A (ko) | 2012-12-04 |
| CA2789750C (en) | 2018-03-06 |
| BR112012020377A2 (pt) | 2016-05-10 |
| MX2012009774A (es) | 2012-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012000275A (es) | Antagonista de bomba de acido para el tratamiento de enfermedades involucradas en la motilidad gastrointestinal anormal. | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| PH12015502628A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| SG150531A1 (en) | Use of meloxicam for the treatment of respiratory diseases in pigs | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2009002196A (es) | Oblea de buprenorfina para terapia de sustitucion de farmacos. | |
| NZ605469A (en) | Nalbuphine-based formulations and uses thereof | |
| NZ602510A (en) | Treatment of lupus nephritis using laquinimod | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| MX2013000001A (es) | Composición farmaceutica de liberacion prolongada y acción retardada que comprende dapoxetina para administaracion oral. | |
| WO2011157416A3 (de) | Transdermale verabreichung von memantin | |
| MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2011011058A (es) | Antagonistas del receptor ep4 para el tratamiento de cancer. | |
| PH12015500823A1 (en) | Modified release formulations for oprozomib | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| WO2008051527A3 (en) | Sustained release of agents for localized pain management | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| WO2007144889A3 (en) | Treatment of neurofibromatosis | |
| WO2012125871A3 (en) | Aconitine compounds, compositions, uses, and preparation thereof | |
| RU2012114097A (ru) | Терапевтический агент против хронической боли |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |